Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 35

1.

Guideline Recommendations for Testing of ALK Gene Rearrangement in Lung Cancer: A Proposal of the Korean Cardiopulmonary Pathology Study Group.

Kim H, Shim HS, Kim L, Kim TJ, Kwon KY, Lee GK, Chung JH; Korean Cardiopulmonary Pathology Study Group.

Korean J Pathol. 2014 Feb;48(1):1-9. doi: 10.4132/KoreanJPathol.2014.48.1.1. Epub 2014 Feb 25. Review.

PMID:
24627688
[PubMed]
Free PMC Article
2.

Crizotinib: A comprehensive review.

Sahu A, Prabhash K, Noronha V, Joshi A, Desai S.

South Asian J Cancer. 2013 Apr;2(2):91-7. doi: 10.4103/2278-330X.110506. Review.

PMID:
24455567
[PubMed]
Free PMC Article
3.

The pivotal role of pathology in the management of lung cancer.

Davidson MR, Gazdar AF, Clarke BE.

J Thorac Dis. 2013 Oct;5(Suppl 5):S463-78. doi: 10.3978/j.issn.2072-1439.2013.08.43. Review.

PMID:
24163740
[PubMed]
Free PMC Article
4.

Crizotinib in the treatment of non-small-cell lung carcinoma.

Płużański A, Piórek A, Krzakowski M.

Contemp Oncol (Pozn). 2012;16(6):480-4. doi: 10.5114/wo.2012.32477. Epub 2013 Jan 4.

PMID:
23788933
[PubMed]
Free PMC Article
5.

Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancer.

Sang J, Acquaviva J, Friedland JC, Smith DL, Sequeira M, Zhang C, Jiang Q, Xue L, Lovly CM, Jimenez JP, Shaw AT, Doebele RC, He S, Bates RC, Camidge DR, Morris SW, El-Hariry I, Proia DA.

Cancer Discov. 2013 Apr;3(4):430-43. doi: 10.1158/2159-8290.CD-12-0440. Epub 2013 Mar 26.

PMID:
23533265
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

ALK inhibitor PF02341066 (crizotinib) increases sensitivity to radiation in non-small cell lung cancer expressing EML4-ALK.

Sun Y, Nowak KA, Zaorsky NG, Winchester CL, Dalal K, Giacalone NJ, Liu N, Werner-Wasik M, Wasik MA, Dicker AP, Lu B.

Mol Cancer Ther. 2013 May;12(5):696-704. doi: 10.1158/1535-7163.MCT-12-0868. Epub 2013 Feb 26.

PMID:
23443800
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Fluorescence in situ hybridization and immunohistochemistry as diagnostic methods for ALK positive non-small cell lung cancer patients.

Martinez P, Hernández-Losa J, Montero MÁ, Cedrés S, Castellví J, Martinez-Marti A, Tallada N, Murtra-Garrell N, Navarro-Mendivill A, Rodriguez-Freixinos V, Canela M, Ramon y Cajal S, Felip E.

PLoS One. 2013;8(1):e52261. doi: 10.1371/journal.pone.0052261. Epub 2013 Jan 24.

PMID:
23359795
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

True 3q chromosomal amplification in squamous cell lung carcinoma by FISH and aCGH molecular analysis: impact on targeted drugs.

Brunelli M, Bria E, Nottegar A, Cingarlini S, Simionato F, Caliò A, Eccher A, Parolini C, Iannucci A, Gilioli E, Pedron S, Massari F, Tortora G, Borze I, Knuutila S, Gobbo S, Santo A, Tondulli L, Calabrò F, Martignoni G, Chilosi M.

PLoS One. 2012;7(12):e49689. doi: 10.1371/journal.pone.0049689. Epub 2012 Dec 6.

PMID:
23236352
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Leptomeningeal carcinomatosis as initial presentation in adenocarcinoma of lung with signet ring cell features: an autopsy case report.

Choi E, Lewis AL, Takei H, Ro JY.

Int J Clin Exp Pathol. 2012;5(9):972-6. Epub 2012 Oct 20.

PMID:
23119115
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Advances in gas chromatographic methods for the identification of biomarkers in cancer.

Kouremenos KA, Johansson M, Marriott PJ.

J Cancer. 2012;3:404-20. doi: 10.7150/jca.4956. Epub 2012 Sep 26.

PMID:
23074381
[PubMed]
Free PMC Article
11.

EML4-ALK fusion transcripts in immunohistochemically ALK-positive non-small cell lung carcinomas.

Shinmura K, Kageyama S, Igarashi H, Kamo T, Mochizuki T, Suzuki K, Tanahashi M, Niwa H, Ogawa H, Sugimura H.

Exp Ther Med. 2010 Mar;1(2):271-275. Epub 2010 Mar 1.

PMID:
22993539
[PubMed]
Free PMC Article
12.

Targetable "driver" mutations in non small cell lung cancer.

Vijayalakshmi R, Krishnamurthy A.

Indian J Surg Oncol. 2011 Sep;2(3):178-88. doi: 10.1007/s13193-011-0108-0. Epub 2011 Dec 17.

PMID:
22942608
[PubMed]
Free PMC Article
13.

Genetic and biochemical alterations in non-small cell lung cancer.

Johnson JL, Pillai S, Chellappan SP.

Biochem Res Int. 2012;2012:940405. doi: 10.1155/2012/940405. Epub 2012 Aug 15.

PMID:
22928112
[PubMed]
Free PMC Article
14.

EML4-ALK testing in non-small cell carcinomas of the lung: a review with recommendations.

Thunnissen E, Bubendorf L, Dietel M, Elmberger G, Kerr K, Lopez-Rios F, Moch H, Olszewski W, Pauwels P, Penault-Llorca F, Rossi G.

Virchows Arch. 2012 Sep;461(3):245-57. doi: 10.1007/s00428-012-1281-4. Epub 2012 Jul 24. Review.

PMID:
22825000
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

ALK-immunoreactive neoplasms.

Minoo P, Wang HY.

Int J Clin Exp Pathol. 2012;5(5):397-410. Epub 2012 May 23. Review.

PMID:
22808292
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Issues surrounding clinical trial endpoints in solid malignancies with a focus on metastatic non-small cell lung cancer.

Garon EB.

Lung Cancer. 2012 Sep;77(3):475-81. doi: 10.1016/j.lungcan.2012.06.007. Epub 2012 Jul 12. Review.

PMID:
22795702
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

The importance of a satisfactory biopsy for the diagnosis of lung cancer in the era of personalized treatment.

Ofiara LM, Navasakulpong A, Ezer N, Gonzalez AV.

Curr Oncol. 2012 Jun;19(Suppl 1):S16-23. doi: 10.3747/co.19.1062.

PMID:
22787407
[PubMed]
Free PMC Article
18.

EML4-ALK fusion gene in Korean non-small cell lung cancer.

Jin G, Jeon HS, Lee EB, Kang HG, Yoo SS, Lee SY, Lee JH, Cha SI, Park TI, Kim CH, Jheon SH, Park JY.

J Korean Med Sci. 2012 Feb;27(2):228-30. doi: 10.3346/jkms.2012.27.2.228. Epub 2012 Jan 27.

PMID:
22323876
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

The role of molecular analyses in the era of personalized therapy for advanced NSCLC.

Tanner NT, Pastis NJ, Sherman C, Simon GR, Lewin D, Silvestri GA.

Lung Cancer. 2012 May;76(2):131-7. doi: 10.1016/j.lungcan.2011.11.013. Epub 2011 Dec 15. Review.

PMID:
22176813
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged non-small cell lung cancer and beyond.

Ou SH.

Drug Des Devel Ther. 2011;5:471-85. doi: 10.2147/DDDT.S19045. Epub 2011 Nov 23. Review.

PMID:
22162641
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk